Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotinamide Riboside in Diabetic Polyneuropathy
NCT03685253Phase 2Terminated
- Sponsor
- University of Maryland, Baltimore
- Start
- Jan 2019
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic polyneuropathy (DPN) comparing Placebo with Niagen® (2 arms). Primary endpoint: Thigh Intraepidermal Nerve Fiber Density at 6 months. Started Jan 2019; status: terminated.
02
Drugs
nicotinamide riboside
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on NCT03685253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03685253.